SartoMax is proud to have played a pivotal role in supporting Opal Bio Pharma (OBP) in its mission to advance biopharmaceutical manufacturing in Oman. This strategic collaboration represents a major milestone in the region’s ongoing journey toward self-sufficiency in biologics production, healthcare innovation, and pharmaceutical independence. By working together, SartoMax and OBP are helping to lay the foundation for a more resilient, responsive, and future-ready healthcare ecosystem in the GCC.
OBP has successfully developed a cutting-edge platform with two powerful expression systems: CHO (Chinese Hamster Ovary) cells and baculovirus-based vectors. These systems are globally recognized for their reliability, scalability, and ability to produce high-quality biologics, including biosimilar therapeutics and vaccines.
The implementation of this advanced platform enables OBP to manufacture biologics in a cost-effective and streamlined manner. This reduces reliance on imported pharmaceutical products and allows for a faster, more localized response to public health needs. By focusing on biosimilars—biologic medicines that are highly similar to already approved reference drugs—OBP is contributing to the democratization of healthcare by making life-saving treatments more affordable and accessible to patients in Oman and neighboring countries. This approach also supports long-term economic growth by fostering domestic expertise and reducing foreign dependency.
This initiative is not only a technological breakthrough but also a strategic move to strengthen regional biomanufacturing infrastructure. It positions Oman as a rising hub for pharmaceutical innovation and contributes to the broader goal of healthcare resilience across the GCC and the Middle East and North Africa (MENA) regions. The ability to produce vaccines and therapeutic biologics locally is especially critical during global health emergencies, such as pandemics, when international supply chains are strained and demand for essential medicines surges. Local production ensures faster deployment, better inventory control, and improved public health outcomes.
SartoMax has been instrumental in streamlining OBP’s operations and accelerating its path to commercial readiness. Our team of seasoned experts has provided end-to-end support in key areas such as process development, scale-up strategies, facility design, and regulatory compliance. By applying advanced bioprocessing techniques and rigorous quality assurance protocols, we have helped OBP achieve consistent product quality, operational efficiency, and regulatory alignment. Our collaborative approach ensures that every stage of development is optimized for performance, safety, and scalability.
SartoMax’s involvement has also played a crucial role in preparing OBP for international expansion. With robust manufacturing systems in place and a strong foundation in regulatory standards, OBP is now well-positioned to extend its reach beyond the GCC into the broader MENA region and other middle-income countries. This opens up exciting opportunities for cross-border collaboration, technology transfer, and export of high-quality biologics—further elevating the region’s profile in the global biopharmaceutical landscape. It also encourages regional investment and fosters innovation ecosystems that benefit both industry and society.
At SartoMax, we believe that innovation flourishes through collaboration. Our partnership with OBP is a testament to what can be achieved when technical expertise, strategic vision, and a shared commitment to public health come together. We are not only helping to build infrastructure but also empowering communities by expanding access to critical biologics that improve lives and support long-term health outcomes. Our shared values and dedication to excellence continue to drive meaningful progress.
Together, SartoMax and OBP are shaping the future of biopharmaceutical manufacturing in the region—driving progress, fostering innovation, and contributing to a healthier, more self-reliant world built on trust, science, and shared purpose.
